Why your insurance might not cover Zepbound (and what to do about it)

Half the questions we get from US-based quiz takers are versions of the same question: "does insurance cover Zepbound?" The answer, for a majority of employer-sponsored plans in 2026, is still no. Here is why, how to check your specific coverage, and what your options are when you get denied.

Why the coverage gap exists

US private health insurance plans generally cover tirzepatide when it is prescribed for type 2 diabetes (brand Mounjaro). Coverage rates for the same molecule under the Zepbound brand (for obesity) are much lower. An October 2024 KFF survey found that roughly 27% of large employer plans covered GLP-1 drugs for weight management. The rate has climbed since but remains well below 50%.

Three reasons:

Cost. At $1,000-1,350 per patient per month list price, covering 5-15% of a workforce adds substantial expense. Employers doing the math estimate $5-15 per member per month (PMPM) cost increase. For a 5,000-employee company, that is a 7-figure annual increase.

Lifetime-use framing. Unlike antibiotics or acute-care drugs, GLP-1 weight drugs are maintenance. Stop-and-regain data from SURMOUNT-4 means employers face an unbounded liability. Once a patient starts, they are likely on it indefinitely.

Wait-and-see on generics and competitors. Semaglutide's patent situation is complex and compounded alternatives are widely available. Some plans are explicitly waiting for more supply competition before covering.

How to check your specific coverage

Before assuming you have no coverage or full coverage:

1. Find your formulary. Your employer's HR portal or your insurer's member site has a drug formulary (list of covered medications). Search for "tirzepatide," "Mounjaro," and "Zepbound" separately. The results tell you the tier and any restrictions.

2. Check the prior authorization (PA) requirements. Even if covered, most plans require PA. Common criteria: BMI >30 (or >27 with comorbidity), documented weight-loss attempts, sometimes proof of physician-supervised diet for 6 months prior. Your prescriber files the PA; you do not.

3. Check step therapy requirements. Some plans require you try phentermine or semaglutide first, fail, and document the failure before they cover tirzepatide.

4. Look for dollar caps. A covered drug can still have a $500 copay per month. "Covered" does not mean "affordable."

5. Ask HR directly. Wellness benefits sometimes include weight-management programs that cover GLP-1 drugs as part of a bundle. These are often not in the standard formulary docs.

The denial pattern

When PA gets denied, the most common reasons:

• BMI under 30 and no qualifying comorbidity (most fixable — if you have sleep apnea, hypertension, PCOS, or pre-diabetes, document it)
• No prior weight-loss attempts documented
• Step therapy not completed
• "Not medically necessary" (appeal-able, often successful on appeal with clinician letter)

Your first denial is usually not final. Appeal rates for GLP-1 drugs vary but 30-50% of appeals succeed when a physician letter is attached.

Legitimate workarounds if you are denied

Option 1: Appeal with physician letter. Have your prescriber write a letter covering your weight history, comorbidities, prior attempts, and the clinical rationale. Appeals often succeed on second or third attempt.

Option 2: Compounded tirzepatide. 503A compounding pharmacies (via telehealth services like Ro, Henry Meds, Mochi, LifeMD) charge $250-500 monthly, substantially less than brand cash price. Quality depends entirely on the pharmacy — see our compounded vs brand guide for how to vet one.

Option 3: Medical tourism to Thailand. Roundtrip from the US to Bangkok is 1,000-1,500 USD. A 3-month clinic supply is 500-1,000 USD. Combined with the consult, it can match 3 months of US brand cash. See our Thailand price analysis.

Option 4: Lilly Cares or savings programs. Eli Lilly has patient assistance programs for low-income and uninsured patients. Income thresholds are strict (typically <400% federal poverty level) but reduce cost substantially for qualifying patients.

Option 5: Employer wellness benefit. Some employers offer stipends or wellness credits that can apply toward weight-management drugs even when the formulary excludes them. Often under-advertised.

Option 6: FSA/HSA. Weight-loss drugs prescribed for a medical condition (obesity, diabetes, PCOS) are eligible for FSA and HSA spending. Not a discount on the drug itself but a meaningful pre-tax savings.

What not to do

Do not buy research-chem tirzepatide online to save money. We have a silent filter specifically for grey-market US vendors. The trust profile is not good. If your insurance denies and compounded telehealth is out of reach, medical tourism is a safer option than research-chem.

Do not lie on prior authorization. "Claim you have diabetes" is sometimes suggested in forums. Insurance fraud risk is real. The PA requires documentation.

Do not switch to a worse drug just to get coverage. If your plan covers semaglutide but not tirzepatide, and tirzepatide is clearly better for you, appeal first before accepting the lower-efficacy drug.

What Panya does

If you indicate US residency in the quiz with a tight budget, we route you to compounded telehealth services that score high on our 11-signal rubric. We do not route brand Zepbound at full cash price unless your quiz signals insurance coverage. We also do not push you to international sourcing unless you flag that you have travel flexibility.

Take the quiz to get the match filtered for your specific situation.

---

Citations: KFF 2024 Employer Health Benefits Survey (October 2024); Eli Lilly Q4 2024 investor disclosure on Zepbound coverage; CMS Medicare Part D coverage guidance 2026; public rate cards from Ro, Henry Meds, Mochi, LifeMD as of April 2026.